.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Citi
Fuji
Federal Trade Commission
Colorcon
AstraZeneca
Express Scripts
McKesson
Novartis
Healthtrust

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,863,288

« Back to Dashboard

Which drugs does patent 7,863,288 protect, and when does it expire?


Patent 7,863,288 protects ZELBORAF and is included in one NDA.

This patent has seventy-three patent family members in thirty-four countries.

Summary for Patent: 7,863,288

Title:Compounds and methods for kinase modulation, and indications therefor
Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
Inventor(s): Ibrahim; Prabha N. (Mountain View, CA), Artis; Dean R. (Kensington, CA), Bremer; Ryan (Oakland, CA), Mamo; Shumeye (Oakland, CA), Zhang; Chao (Moraga, CA), Zhang; Jiazhong (Foster City, CA), Tsai; James (Vallejo, CA), Hirth; Klaus-Peter (San Francisco, CA), Bollag; Gideon (Orinda, CA), Spevak; Wayne (Berkeley, CA), Cho; Hanna (Oakland, CA), Gillette; Samuel J. (Oakland, CA), Shi; Shenghua (San Diego, CA)
Assignee: Plexxikon, Inc. (Berkeley, CA)
Application Number:11/473,347
Patent Claim Types:
see list of patent claims
Compound; Composition; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hoffmann La RocheZELBORAFvemurafenibTABLET;ORAL202429-001Aug 17, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,863,288

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,846,941Compounds modulating c-kit and c-fms activity and uses therefor► Subscribe
8,470,818Compounds and methods for kinase modulation, and indications therefor► Subscribe
8,415,469Compounds and methods for kinase modulation, and indications therefor► Subscribe
8,143,271Compounds and methods for kinase modulation, and indications therefor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,863,288

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China102603581► Subscribe
Costa Rica9591► Subscribe
Costa Rica9677► Subscribe
Costa Rica20130216► Subscribe
Cyprus1111996► Subscribe
Cyprus1117553► Subscribe
Germany122012000043► Subscribe
Denmark1893612► Subscribe
Denmark2395004► Subscribe
EcuadorSP077985► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
US Army
QuintilesIMS
Argus Health
Moodys
Julphar
Chubb
Johnson and Johnson
Covington
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot